olmesartan has been researched along with Disease Exacerbation in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirohata, A; Ito, H; Komatsubara, I; Kusachi, S; Miyoshi, T; Murakami, T; Nakamura, K; Ohe, T; Usui, S; Yamamoto, K | 1 |
| Amano, T; Harada, K; Ichimiya, S; Ishii, H; Kanashiro, M; Kobayashi, M; Kurebayashi, N; Marui, N; Murohara, T; Sone, T; Suzuki, S; Tsuboi, H; Uetani, T; Yoshikawa, D | 1 |
| Armstrong, ZB; Boughner, DR; Carruthers, CP; Drangova, M; Rogers, KA | 1 |
| Baek, SH; Chin, HJ; Choi, BS; Kim, DK; Kim, S; Lee, SH; Lim, CS; Park, JH; Shin, SJ | 1 |
| Fan, YY; Fujisawa, Y; Hase, N; Hitomi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsuura, J; Nakano, D; Nishiyama, A; Urata, H | 1 |
| Hatanaka, K; Hina, K; Hirohata, A; Hirohata, S; Hirose, E; Ishizawa, M; Kawamura, H; Komatsubara, I; Kusachi, S; Miyoshi, T; Murakami, M; Murakami, T; Ohe, T; Ohkawa, K; Sato, S; Yamaji, H; Yamamoto, K; Yamawaki, H | 1 |
| Marso, SP | 1 |
| Bakris, G; Haller, H; Izzo, J; Oparil, S; Ruilope, L; Sowers, J; Waeber, B; Weber, M | 1 |
| Chen, R; Eisner, C; Hu, X; Huang, Y; Kopp, JB; Leelahavanichkul, A; Mizel, D; Schnermann, J; Star, RA; Wright, EC; Yan, Q; Yuen, PS; Zhou, H | 1 |
| Kim, HJ; RodrÃguez-Iturbe, B; Sato, T; Vaziri, ND | 1 |
| Hatanaka, K; Hirohata, A; Hirohata, S; Hirose, E; Ito, H; Kobayashi, Y; Komatsubara, I; Kusachi, S; Miyoshi, T; Ohara, M; Ohe, T; Ohkawa, K; Sano, F; Takafuji, H; Toyama, Y; Yamamoto, K; Yamawaki, H | 1 |
| Chatzikyrkou, C; Menne, J | 1 |
| Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Liao, Y; Minamino, T; Nagamachi, Y; Nakatani, T; Ogawa, S; Okada, K; Ozawa, K; Takashima, S; Tomoike, H; Tsukamoto, O; Tsukamoto, Y; Yutani, C | 1 |
| Schmieder, RE | 1 |
| Averill, DB; Brosnihan, KB; Ferrario, CM; Schiffrin, EL; Smith, RD; Yokoyama, H | 1 |
| Halimi, S | 1 |
3 review(s) available for olmesartan and Disease Exacerbation
| Article | Year |
|---|---|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endothelium, Vascular; Humans; Imidazoles; Renin-Angiotensin System; Risk Factors; Tetrazoles | 2010 |
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Imidazoles; Incidence; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Metabolic Syndrome; Multicenter Studies as Topic; Placebos; Primary Prevention; Randomized Controlled Trials as Topic; Rats; Rats, Inbred Strains; Risk Factors; Sex Factors; Tetrazoles; Time Factors; Treatment Outcome | 2005 |
5 trial(s) available for olmesartan and Disease Exacerbation
| Article | Year |
|---|---|
Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.
Topics: Adiponectin; Aged; Angina, Stable; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Disease Progression; Down-Regulation; Female; Humans; Imidazoles; Inflammation Mediators; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypertension; Image Interpretation, Computer-Assisted; Imidazoles; Long-Term Care; Male; Middle Aged; Tetrazoles; Ultrasonography, Interventional; Valine; Valsartan | 2013 |
A low-salt diet increases the estimated net endogenous acid production in nondiabetic chronic kidney disease patients treated with angiotensin receptor blockade.
Topics: Acid-Base Equilibrium; Angiotensin II Type 1 Receptor Blockers; Diet, Sodium-Restricted; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Tetrazoles; Treatment Outcome; Urinalysis | 2014 |
Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Survival Rate; Tetrazoles; Ultrasonography, Interventional | 2010 |
Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Cerebrovascular Disorders; Chi-Square Distribution; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Female; Heart Diseases; Humans; Imidazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
8 other study(ies) available for olmesartan and Disease Exacerbation
| Article | Year |
|---|---|
Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a preclinical model.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Valve; Atorvastatin; Bicuspid Aortic Valve Disease; Disease Progression; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Imidazoles; Immunohistochemistry; Male; Pyrroles; Rabbits; Random Allocation; Sclerosis; Tetrazoles | 2014 |
Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blood Urea Nitrogen; Butyrates; Chymases; Collagen Type I; Cricetinae; Disease Progression; Imidazoles; Kidney; Male; Mesocricetus; Nephritis, Interstitial; Organ Size; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Transforming Growth Factor beta; Ureteral Obstruction | 2009 |
Plaque burden with composition? That is the next question.
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Combined Modality Therapy; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Ultrasonography, Interventional | 2010 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Fibrosis; Genetic Predisposition to Disease; Glomerulonephritis; Heart Diseases; Hydralazine; Hypertension; Imidazoles; Infusion Pumps, Implantable; Infusions, Subcutaneous; Kidney; Kidney Diseases; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Nephrectomy; Sodium Chloride, Dietary; Species Specificity; Telemetry; Tetrazoles; Time Factors; X-Ray Microtomography | 2010 |
Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Glomerulosclerosis, Focal Segmental; Hypertension; Imidazoles; Kidney; Kidney Diseases; Male; NF-E2 Transcription Factor; NF-kappa B; Oxidative Stress; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Thiobarbituric Acid Reactive Substances | 2011 |
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Apoptosis; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Disease Progression; Endoplasmic Reticulum; Gene Expression Regulation; Heart Failure; Humans; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocytes, Cardiac; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Rats; Rats, Inbred WKY; RNA, Messenger; Signal Transduction; Stress, Physiological; Tetrazoles; Thapsigargin; Tunicamycin | 2004 |
["High dosage monotherapy"].
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Imidazoles; Patient Compliance; Proteinuria; Tetrazoles | 2005 |
Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiomegaly; Collagen; Disease Progression; Endothelium, Vascular; Heart Rate; Hypertension; Imidazoles; Male; Mesenteric Arteries; Myocardium; Rats; Rats, Inbred SHR; Tetrazoles; Vascular Diseases; Vascular Resistance | 2005 |